Location History:
- Essex, GB (2012 - 2013)
- Buckinghamshire, GB (2014 - 2015)
Company Filing History:
Years Active: 2012-2015
Title: Innovations in Respiratory Treatments by Craig Fox
Introduction
Craig Fox, an accomplished inventor based in Buckinghamshire, GB, has made significant contributions to the field of respiratory disease treatment. With a total of four patents to his name, his innovations are primarily focused on enhancing the efficacy of pharmaceutical compositions designed for pulmonary administration.
Latest Patents
Craig's latest patents revolve around respiratory disease treatment. One notable invention includes a pharmaceutical composition that is adapted for pulmonary administration by inhalation. This composition comprises a glitazone, specifically pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients. The patent specifies that the glitazone content consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, with the glitazone being in the form of microparticles. This innovative formulation highlights the potential for targeted therapies in the treatment of respiratory conditions.
Another patent presented by Craig outlines a similar pharmaceutical composition, again adapted for pulmonary administration. The composition includes a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, emphasizing the importance of the 5R enantiomer content. Additionally, it mentions a use and kit, demonstrating the practical applications of his research in a clinical setting.
Career Highlights
Throughout his career, Craig has been affiliated with prominent organizations that focus on respiratory health. He has worked at Pulmagen Therapeutics Limited, where he contributed to advancements in inflammation-related treatments. His expertise in pharmaceutical formulations has driven significant progress in respiratory disease management.
Collaborations
Craig Fox has collaborated with several esteemed colleagues, including Harry Finch and Mohammed Sajad. Their collective expertise has fostered innovative approaches to developing effective treatments for respiratory conditions, further enhancing the impact of Craig's inventions.
Conclusion
In conclusion, Craig Fox's dedication to innovating respiratory treatments demonstrates his commitment to improving patient outcomes. His patents not only reflect his technical prowess but also hold promise for future advancements in pharmaceutical formulations targeting respiratory diseases. As he continues to work in collaboration with other experts, Craig's contributions to the medical field are likely to make a lasting impact.